Breaking Finance News

Jefferies International covered GlaxoSmithKline PLC (LON:GSK), bumping its target to 1,950.00GBX today

Reporting a possible upside of 0.14%, Jefferies International upped the price target of GlaxoSmithKline PLC (LON:GSK) to 1,950.00GBX

Previously on Wednesday October 05, 2016, Citigroup reported on GlaxoSmithKline PLC (LON:GSK) held steady the target price at 1,800.00GBX that suggested an upside of 0.07%.

Displaying a price of 1,707.50GBX, GlaxoSmithKline PLC (LON:GSK) traded -0.53% lower on the day. With the last stock price up 8.26% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the date range. The company has recorded a 50-day moving average of 1,650.69GBX and a two hundred day average of 1,561.99GBX. Trade Volume was up over the average, with 8,982,261 shares of GSK changing hands over the typical 7,639,810

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline PLC has a P/E ratio of 2,818.33 with a 52 week low of 1,277.25GBX and a one year high of 1,745.56GBX GSK’s total market value is currently 0 GBX.

Also covering GlaxoSmithKline PLC's price target, a total of 24 equity analysts have released a ratings update on the company. The average stock price target is 1,577.33GBX with 3 brokerages rating the stock a strong buy, 6 brokers rating the stock a buy, seventeen analysts rating the company a hold, 2 firms rating the stock a underperform, and finally zero equity analysts rating the stock a sell.

General Information About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.